Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 13 August 2013
[DOI: 10.1126/scisignal.2004008]

Supplementary Materials for:

Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK
and AKT Inhibitors

Daniel C. Kirouac,* Jin Y. Du, Johanna Lahdenranta, Ryan Overland, Defne Yarar, Violette Paragas, Emily Pace, Charlotte F. McDonagh, Ulrik B. Nielsen, Matthew D. Onsum

*Corresponding author. E-mail: dkirouac{at}merrimackpharma.com

This PDF file includes:

  • Fig. S1. Time-course proteomic responses to MM-111 and lapatinib treatment.
  • Fig. S2. Relative abundance of total ErbB3 versus phosphorylated AKT and ERK in response to MM-111 and lapatinib combination treatments.
  • Fig. S3. Molecular responses to PI3K and MEK inhibition across a panel of 20 cell lines.
  • Fig. S4. Simulated ErbB3-mediated crosstalk between PI3K/AKT and MAPK/ERK pathways.
  • Fig. S5. Transcriptional feedback circuits regulate ErbB3 abundance and activation.
  • Fig. S6. Weighted sum squared error (WSSE) for nine alternative logic models of cell growth.
  • Fig. S7. Functional significance of feedback circuits.
  • Fig. S8. Mutational status and relative resistance or sensitivity to combination drug treatment.
  • Fig. S9. Cell-surface abundance of ErbB2 and ErbB3 is not affected by MM-111 treatment.
  • Fig. S10. Correlations between total ErbB2, ErbB3, and phosphorylated ErbB2 abundance across a panel of 82 cancer cell lines.
  • Fig. S11. Simulation of lapatinib pharmacokinetics over a range of oral absorption (ka) rates.
  • Table S1. Model variables.
  • Table S2. Model parameters.
  • Table S3. Antibodies used in Luminex assays.
  • Table S4. Cell lines included in basal protein profiling.

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 4.12 MB


Citation: D. C. Kirouac, J. Y. Du, J. Lahdenranta, R. Overland, D. Yarar, V. Paragas, E. Pace, C. F. McDonagh, U. B. Nielsen, M. D. Onsum, Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors. Sci. Signal. 6, ra68 (2013).

© 2013 American Association for the Advancement of Science


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882